Volume 25, Number 2—February 2019
Research
Zika Virus IgM Detection and Neutralizing Antibody Profiles 12–19 Months after Illness Onset
Table 1
Characteristic | No. (%) enrolled,* n = 62 | No. (%) not enrolled,* n = 290 | p value† |
---|---|---|---|
Age group, y | 0.19 | ||
1–18 | 2 (3) | 26 (9) | |
19–64 | 54 (87) | 247 (85) | |
>65 |
6 (10) |
17 (6) |
|
Sex | 0.85 | ||
M | 32 (52) | 146 (50) | |
F |
30 (48) |
144 (50) |
|
Race/ethnicity | 0.55 | ||
Non-Hispanic white | 13 (21) | 41 (14) | |
Non-Hispanic African American | 3 (5) | 14 (5) | |
Hispanic | 42 (68) | 209 (72) | |
Unknown |
4 (6) |
26 (9) |
|
Main symptoms of Zika virus disease‡ | 0.88 | ||
1 of 4 | 2 (3) | 12 (4) | |
2 of 4 | 15 (24) | 78 (27) | |
3 of 4 | 32 (52) | 130 (45) | |
4 of 4 |
13 (21) |
69 (24) |
|
Origin of infection | 0.19 | ||
Florida | 34 (55) | 133 (46) | |
Outside Florida | 28 (45) | 157 (54) |
*All percentages are column percentages.
†A p value <0.05 was considered statistically significant.
‡Main symptoms were defined as fever, maculopapular rash, arthralgia, and conjunctivitis.
Page created: January 16, 2019
Page updated: January 16, 2019
Page reviewed: January 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.